Abstract
AbstractThe current study evaluated retinal function using electroretinography (ERG) in cognitively healthy (CH) participants with preclinical Alzheimer’s disease (AD), as classified by cerebral spinal fluid (CSF) Aβ42/Tau ratio. Individuals with normal retinal morphology ascertained by spectral-domain optical coherence tomography were enrolled. Full-field ERG, pattern PERG, and photopic negative response (PhNR) were performed in 29 adult participants (58 eyes). Amplitude and implicit times of the ERG wave components were analyzed. Preclinical AD participants showed marked retinal ganglion cell dysfunction relative to controls. The PhNR was significantly diminished in preclinical AD relative to controls. PhNR amplitude and N95 implicit time differentiated CH individuals with CSF biomarkers of AD pathology with 87% sensitivity and 82% specificity. These quantitative electrophysiologic findings expand our understanding of early retinal functional changes that precede cognitive decline in AD. Retinal ganglion cell dysfunction, as detected by ERG, may be a clinically useful, non-invasive in vivo biomarker for early disease detection, which is necessary for ultimately pursuing early intervention.
Funder
Research to Prevent Blindness
L.K. Whittier Foundation, Brain Aging Study
U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging
International Foundation for Optic Nerve Diseases
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Alzheimer’s Association,. Alzheimer’s disease facts and figures. Alzheimers Dement. 16, 391–460 (2020).
2. Batsch, N. L. & Mittelman, M. S. World Alzheimer Report 2012: Overcoming the Stigma of Dementia Vol. 5 (Alzheimer’s Disease International, London, 2012).
3. McKhann, G. et al. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939–939 (1984).
4. Katz, B. & Rimmer, S. Ophthalmologic manifestations of Alzheimer’s disease. Surv. Ophthalmol. 34, 31–43 (1989).
5. Tzekov, R. & Mullan, M. Vision function abnormalities in Alzheimer disease. Surv. Ophthalmol. 59, 414–433 (2014).
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献